BioWorld

Feb. 20, 2007

Ziopharm Adds $31M For Clinical Oncology Pipeline

Ziopharm Oncology Inc. pulled in gross proceeds of $30.9 million in a private placement to advance ongoing clinical development of three lead cancer programs, two of which are expected enter pivotal testing this year. (BioWorld Today) Read More

Inspire Pads Late-Stage Pipeline With License To InSite's AzaSite

In Irritable Bowel Syndrome Pain, A General Mechanism

FDA Says No Strings Attached To PDUFA At Public Meeting

Holiday Notice

GPC's Satraplatin NDA Done, Drug Could Launch This Year

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Illustration of a nerve cell with DNA double helix

Molecular signatures show subtypes in neurodegenerative diseases

BioWorld Science

Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...